298 related articles for article (PubMed ID: 28698206)
1. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
Szydłowski M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Derezińska E; Hoser G; Wasilewska D; Szymańska-Giemza O; Jabłońska E; Białopiotrowicz E; Sewastianik T; Polak A; Czardybon W; Gałęzowski M; Windak R; Zaucha JM; Warzocha K; Brzózka K; Juszczyński P
Blood; 2017 Sep; 130(12):1418-1429. PubMed ID: 28698206
[TBL] [Abstract][Full Text] [Related]
2. PIM Kinases Promote Survival and Immune Escape in Primary Mediastinal Large B-Cell Lymphoma through Modulation of JAK-STAT and NF-κB Activity.
Szydłowski M; Dębek S; Prochorec-Sobieszek M; Szołkowska M; Tomirotti AM; Juszczyński P; Szumera-Ciećkiewicz A
Am J Pathol; 2021 Mar; 191(3):567-574. PubMed ID: 33307035
[TBL] [Abstract][Full Text] [Related]
3. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
[TBL] [Abstract][Full Text] [Related]
4. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.
Schatz JH; Oricchio E; Wolfe AL; Jiang M; Linkov I; Maragulia J; Shi W; Zhang Z; Rajasekhar VK; Pagano NC; Porco JA; Teruya-Feldstein J; Rosen N; Zelenetz AD; Pelletier J; Wendel HG
J Exp Med; 2011 Aug; 208(9):1799-807. PubMed ID: 21859846
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma.
Schmitz R; Stanelle J; Hansmann ML; Küppers R
Annu Rev Pathol; 2009; 4():151-74. PubMed ID: 19400691
[TBL] [Abstract][Full Text] [Related]
6. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma.
Juszczynski P; Ouyang J; Monti S; Rodig SJ; Takeyama K; Abramson J; Chen W; Kutok JL; Rabinovich GA; Shipp MA
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13134-9. PubMed ID: 17670934
[TBL] [Abstract][Full Text] [Related]
7. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
[TBL] [Abstract][Full Text] [Related]
8. PIM kinases 1, 2 and 3 in intracellular LIF signaling, proliferation and apoptosis in trophoblastic cells.
Mary Photini S; Chaiwangyen W; Weber M; Al-Kawlani B; Favaro RR; Jeschke U; Schleussner E; Morales-Prieto DM; Markert UR
Exp Cell Res; 2017 Oct; 359(1):275-283. PubMed ID: 28729093
[TBL] [Abstract][Full Text] [Related]
9. A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
Zahn M; Marienfeld R; Melzner I; Heinrich J; Renner B; Wegener S; Mießner A; Barth TF; Dorsch K; Brüderlein S; Möller P
Blood; 2017 Mar; 129(11):1480-1490. PubMed ID: 28082443
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
11. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
12. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
Nagpal P; Descalzi-Montoya DB; Lodhi N
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1311. PubMed ID: 33103852
[TBL] [Abstract][Full Text] [Related]
13. The role of interleukin 13 in classical Hodgkin lymphoma.
Skinnider BF; Kapp U; Mak TW
Leuk Lymphoma; 2002 Jun; 43(6):1203-10. PubMed ID: 12152987
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells.
Horie R; Watanabe T; Ito K; Morisita Y; Watanabe M; Ishida T; Higashihara M; Kadin M; Watanabe T
Am J Pathol; 2002 May; 160(5):1647-54. PubMed ID: 12000717
[TBL] [Abstract][Full Text] [Related]
15. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
Yadav AK; Kumar V; Bailey DB; Jang BC
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
[TBL] [Abstract][Full Text] [Related]
16. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
17. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
[TBL] [Abstract][Full Text] [Related]
18. A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia.
Czardybon W; Windak R; Gołas A; Gałęzowski M; Sabiniarz A; Dolata I; Salwińska M; Guzik P; Zawadzka M; Gabor-Worwa E; Winnik B; Żurawska M; Kolasińska E; Wincza E; Bugaj M; Danielewicz M; Majewska E; Mazan M; Dubin G; Noyszewska-Kania M; Jabłońska E; Szydłowski M; Sewastianik T; Puła B; Szumera-Ciećkiewicz A; Prochorec-Sobieszek M; Mądro E; Lech-Marańda E; Warzocha K; Tamburini J; Juszczyński P; Brzózka K
Oncotarget; 2018 Mar; 9(24):16917-16931. PubMed ID: 29682194
[TBL] [Abstract][Full Text] [Related]
19. Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma.
von Hoff L; Kärgel E; Franke V; McShane E; Schulz-Beiss KW; Patone G; Schleussner N; Kolesnichenko M; Hübner N; Daumke O; Selbach M; Akalin A; Mathas S; Scheidereit C
Blood; 2019 Mar; 133(13):1489-1494. PubMed ID: 30696620
[TBL] [Abstract][Full Text] [Related]
20. JAK/STAT blockade reverses the malignant phenotype of Hodgkin and Reed-Sternberg cells.
Fernández S; Solórzano JL; Díaz E; Menéndez V; Maestre L; Palacios S; López M; Colmenero A; Estévez M; Montalbán C; Martínez Á; Roncador G; García JF
Blood Adv; 2023 Aug; 7(15):4135-4147. PubMed ID: 36459489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
